University of Pavia, Department of Internal Medicine and Therapeutics, 27100 Pavia, Italy.
Expert Opin Pharmacother. 2010 Aug;11(12):1971-82. doi: 10.1517/14656566.2010.493557.
To evaluate the effects of 1-year treatment with orlistat compared with placebo on different inflammatory parameters in type 2 obese diabetic patients.
Two hundred and fifty-four type 2 diabetic patients were randomized to take orlistat 120 mg three times a day or placebo for 12 months. We evaluated at baseline and after 3, 6, 9 and 12 months: leptin, tumor necrosis factor (TNF)-alpha, adiponectin (ADN), vaspin and high-sensitivity C-reactive protein (HS-CRP), body weight, waist circumference, body mass index (BMI), lipid profile, glycemic profile, fasting plasma insulin (FPI) and homeostasis model assessment insulin resistance index (HOMA-IR).
Regarding inflammatory parameters, there was a significant improvement of ADN and TNF-alpha, and a faster decrease of leptin and HS-CRP in the orlistat group compared with the control group. We also recorded a significant reduction of body weight and BMI with orlistat, but not with placebo. A faster improvement of glycemic profile and FPI was obtained with orlistat compared with the controls. Also, there was a significant reduction of lipid profile with orlistat, not reached with placebo.
Orlistat was more effective than placebo in ameliorating inflammatory parameters such as ADN and TNF-alpha, and anthropometric parameters.
评估与安慰剂相比，奥利司他治疗 1 年对 2 型肥胖糖尿病患者不同炎症参数的影响。
254 例 2 型糖尿病患者随机分为奥利司他 120mg，每日 3 次或安慰剂治疗 12 个月。我们在基线和治疗后 3、6、9 和 12 个月评估：瘦素、肿瘤坏死因子（TNF）-α、脂联素（ADN）、vaspin 和高敏 C 反应蛋白（HS-CRP）、体重、腰围、体重指数（BMI）、血脂谱、血糖谱、空腹血浆胰岛素（FPI）和稳态模型评估胰岛素抵抗指数（HOMA-IR）。
关于炎症参数，与对照组相比，奥利司他组 ADN 和 TNF-α显著改善，瘦素和 HS-CRP 下降更快。与安慰剂相比，奥利司他组还记录到体重和 BMI 的显著降低。与对照组相比，奥利司他组血糖谱和 FPI 的改善更快。此外，奥利司他组的血脂谱显著降低，而安慰剂组则没有达到这一效果。
与安慰剂相比，奥利司他在改善 ADN 和 TNF-α等炎症参数以及人体测量参数方面更有效。
